OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacology & Therapeutics is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Editorial Board	366
Adenosine receptor signalling as a driver of pulmonary fibrosis	332
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	286
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	237
The role of macrophages in asthma-related fibrosis and remodelling	237
Collateral lethality: A unique type of synthetic lethality in cancers	219
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	212
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	206
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	197
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	189
Inflammation, lipids, and pain in vulvar disease	178
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	160
Matrikines in the skin: Origin, effects, and therapeutic potential	148
Treatment strategies for leptomeningeal disease in patients with breast cancer	145
Unfolded protein responses: Dynamic machinery in wound healing	143
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	141
Potential neonatal toxicity of new psychoactive substances	141
Non-canonical G protein signaling	131
Treatment approaches for alcohol use disorder with metabolic dysfunction	126
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	122
Endothelial dysfunction as a complication of anti-cancer therapy	119
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	117
Management of drug-resistant hypertension as a heterogeneous disorder	117
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	107
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	105

Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	101
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	100
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	98
TAAR1 as an emerging target for the treatment of psychiatric disorders	97
Cell-based therapies for vascular regeneration: Past, present and future	95
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	95
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	95
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	95
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	93
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	92
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	91
Contribution of non-selective membrane channels and receptors in epilepsy	90
Boron in cancer therapeutics: An overview	90
Dysregulation of metabolic pathways in pulmonary fibrosis	89
Editorial Board	89
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	84
Review: Sex-related differences in the treatment of cardiac arrhythmia	84
Bispecific antibodies for the treatment of neuroblastoma	81
Wnt signaling: A prospective therapeutic target for chronic pain	80
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	78
PGRMC1: An enigmatic heme-binding protein	78
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	76
Pharmacological treatment of cardiogenic shock – A state of the art review	74
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	74
Editorial Board	73
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	72
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	70
Natural products that alleviate depression: The putative role of autophagy	70
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	69
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	69
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	68
DNA methylation in cell plasticity and malignant transformation in liver diseases	67
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	66
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	66
Stabilizing the neural barrier – A novel approach in pain therapy	65
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	64
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	63
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	62